The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently received multi-million dollar funding from the UK government to move forward with a clinical trial. Preparations for the clinical trial are well underway and the trial will begin as soon as possible.
The PharmaJet System was chosen due to its record of increasing the efficacy of nucleic acid-based vaccines and therapeutics.
DIOSynVax's innovative approach uses computer modeling of the virus's structure to identify the distinct genetic code.
The combined artificial intelligence and synthetic biology approach allows for development of a vaccine that is specific to developing antibodies against the SARS-CoV-2 virus.
PharmaJet's mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market.
The PharmaJet Needle-free Systems are safe, fast and easy-to-use.
They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.
The Stratis System has US FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.
The Tropis System has CE Mark and WHO PQS certification for intradermal injections.
DIOSynVax is a spin-out company from the University of Cambridge, set up in 2017 with the support of Cambridge Enterprise, the University's commercialization arm.
Their DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) technology will significantly accelerate vaccine antigen development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral haemorrhagic fevers.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT